Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

Also called NCT03409744

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 116 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03409744
  • EudraCT 2017-003170-13
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Netherlands, South Africa, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03409744. Allocation not applicable; no masking; primary purpose treatment. Start 2018-03-13 (actual); primary completion 2023-04-13 (actual). Results posted on 2024-04-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Condition
Homozygous Familial Hypercholesterolemia
Intervention (Drug)
evinacumab
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03409744
Content hash
179ed56aa7c6e1086627e5a9d247ccc66dd35ef58c4bc938e1a51dfb2125d1b7